How Has the Fibromyalgia Treatment Market Size Evolved in Recent Years?
The fibromyalgia treatment market has seen considerable growth due to a variety of factors.
• In the past few years, the size of the fibromyalgia treatment market has consistently expanded. The progression from $2.79 billion in 2024 to $2.9 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 3.9%.
As a result of the increased frequency of fibromyalgia cases, heightened fibromyalgia awareness, government-efforts, and increasing disposable income, this historical period saw substantial growth.
What Is The Forecast For The Fibromyalgia Treatment Market Size?
The fibromyalgia treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for treating fibromyalgia is projected to witness consistent expansion in the upcoming years. The anticipated growth is to reach $3.45 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 4.5%.
The progress during the forecast period could be due to factors such as an aging population, heightened healthcare spending, an increased number of musculoskeletal disorder cases, and escalated research and development operations for improved treatments. The forecast period is also expected to witness significant trends like enhanced treatment methods, tactical partnerships, incorporation of advanced technology, and innovative therapies.
What Are The Essential Drivers Behind The Growth Of The Fibromyalgia Treatment Market?
Government-led initiatives targeted at musculoskeletal conditions are projected to boost the fibromyalgia market. Governmental initiatives include specific projects, actions, policies, or programs introduced by the government to address societal issues, facilitate economic growth, enhance the quality of public services, or accomplish specific objectives that are beneficial to the country and its people. Major governmental organizations are launching various initiatives to provide support to those battling musculoskeletal conditions. In 2022, for example, the Australian government launched the Own Your Health programme, as per Musculoskeletal Australia, an Australian organization. This program aims to encourage self-care among patients with musculoskeletal conditions over the next four years. As a result, the focus on such governmental initiatives for musculoskeletal conditions is expected to enhance the fibromyalgia market. Market Driver for Fibromyalgia Treatment: Growth in Elderly Population Boosts the Fibromyalgia Treatment Market
How Is The Global Fibromyalgia Treatment Market Divided Into Key Segments?
The fibromyalgia treatment market covered in this report is segmented –
1) By Type: Symptomatic Treatment, Targeted Treatment
2) By Drug Class: Antidepressants, Antiepileptics, Muscle Relaxants, Analgesics, Other Drugs
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Symptomatic Treatment: Pain Relievers, Antidepressants, Anti-seizure Medications, Sleep Aids, Physical Therapy
2) By Targeted Treatment: Cognitive Behavioral Therapy (CBT), Lifestyle Modifications, Complementary Therapies, Medications Targeting Specific Symptoms
Pre-Book The Fibromyalgia Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Fibromyalgia Treatment Market?
Leading companies in the fibromyalgia treatment market are concentrating on designing highly advanced solutions like microchip technology, in order to maintain their stronghold in the market. This specialised type of microchip technology uses a microchip for accurate and targeted nerve stimulation to decrease symptoms related to fibromyalgia. For example, NeuroMetrix Inc., a medical equipment producer based in the US, introduced a Quell Fibromyalgia device in November 2022 via the Pathfinder Program, providing a unique solution for reducing fibromyalgia symptoms. The Quell Fibromyalgia, the only medical device approved by the U.S. Food and Drug Administration (FDA) to relieve fibromyalgia symptoms, employs transcutaneous electrical nerve stimulation (TENS). Enabled by proprietary microchip technology, this device delivers precise, high-intensity nerve stimulation in a compact, wearable format that is optimized through position and motion sensing.
Who Are the Key Players In The Fibromyalgia Treatment Market?
Major companies operating in the fibromyalgia treatment market are:
• Pfizer Inc.
• Johnson and Johnson Services Inc.
• Roche Holding AG
• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Mylan N.V.
• Astellas Pharma Inc.
• Biogen Inc.
• Daiichi Sankyo Co. Ltd.
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Horizon Therapeutics PLC
• Endo International PLC
• Amneal Pharmaceuticals Inc.
• Zydus Lifesciences Limited
• Lupin Limited.
What Are The Regional Insights Into The Fibromyalgia Treatment Market?
North America was the largest region in the fibromyalgia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fibromyalgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
